Thrombomodulin (1009) Mouse Monoclonal Antibody
Specialties: Anatomic Pathology
Thrombomodulin is a transmembrane glycoprotein composed of 575 amino acids (molecular weight 75 kD) with natural anticoagulant properties. It is normally expressed by a restricted number of cells, such as endothelial and mesothelial cells. In addition, synovial lining and syncytiotrophoblasts of human placenta also express thrombomodulin.1-3 Anti-thrombomodulin has demonstrated positivity in benign vascular tumors such as hemangioma and most malignant vascular tumors (Kaposi’s sarcoma and epitheliod hemangioendothelioma).1-2 Hence, anti-thrombomodulin serves as a sensitive marker for lymphatic endothelial cells and their tumors.1-2 There has also been recent interest in the use of anti-thrombomodulin as an immunohiostochemical marker for mesothelial cells and malignant mesotheliomas.3-8 Anti-thrombomodulin is immunoexpressed in a variety of other tumors including urothelial cell carcinomas.9,10
- Acebo E, et al. Thrombomodulin, calretinin and c-kit (CD117) expression in cardiac myxoma. Histol. Histopath. 2001; 16:1031-6.
- Appleton MA, et al. Thrombomodulin as a marker of vascular and lymphatic tumors. Histopathology. 1996; 29:153-7.
- Attanoos RL, et al. Mesothelioma-binding antibodies: Thrombomodulin, OV632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology. 1996; 29:209-15.
- Attanoos RL, et al. Malignant epitheliod mesothelioma: anti-mesothelial marker expression correlates with histological pattern. Histopathology. 2001; 39:584-8.
- Attanoos RL, et al. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma. Histopathology. 2002; 41:42-9.
- Brown RW, et al. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum. Pathol. 1993; 24:347-54.
- Collins CL, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am. J. Pathol. 1992; 141:827-33.
- Doglioni C, et al. Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996; 20:1037-46.
- Chuang AY, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007; 31:1246-55.
- Dabbs DJ. Diagnostic Immunohistochemistry; Theranostic and Genomic Applications. 3rd. Edition. Sauders Elsevier. 2010. p234-5.
Specifications
- Reactivity: paraffin
- Visualization: cytoplasmic, membranous
- Control: bladder, mesothelioma
- Dilution Range: 1:25-1:100*
Package Inserts
IFU
- IVD Rev. 4.0 (CMC33921040)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 339M-14 |
| 0.5 mL concentrate | 339M-15 |
| 1 mL concentrate | 339M-16 |
| 1 mL predilute | 339M-17 |
| 7 mL predilute | 339M-18 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 339M-14 |
| 0.5 mL concentrate | 339M-15 |
| 1 mL concentrate | 339M-16 |
| 1 mL predilute | 339M-17 |
| 7 mL predilute | 339M-18 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 339M-14 |
| 0.5 mL concentrate | 339M-15 |
| 1 mL concentrate | 339M-16 |
| 1 mL predilute | 339M-17 |
| 7 mL predilute | 339M-18 |
For research use only (RUO) in Japan
| 0.1 mL concentrate | 339M-14-RUO |
| 0.5 mL concentrate | 339M-15-RUO |
| 1 mL concentrate | 339M-16-RUO |
| 1 mL predilute | 339M-17-RUO |
| 7 mL predilute | 339M-18-RUO |
To request information on this product in additional countries, please click the button below.